Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Aldosterone Blockade in Chronic Kidney Disease. Influence on Arterial Stiffness and Kidney Function
Brief Summary: Patients with Chronic Kidney Disease (CKD) have a poor prognosis primarily due to cardiovascular disease. The cardiovascular risk can be assessed by measurements of arterial stiffness. A decrease in stiffness has been shown to decrease the risk of cardiovascular disease as well as death. Most of the CKD population also have hypertension and the control of blood pressure is one of the corner stones in inhibition of disease progression. Using drugs that specifically block the renin-angiotensin-system for blood pressure control has been shown to have a beneficial impact on inhibition of progression beyond that of the achieved blood pressure control. It has been reported that inhibition of the hormone aldosterone has a positive effect on survival in patients with heart failure, hypertension and diabetic as well as on-diabetic nephropathy.

This study undertakes the investigation of the influence on arterial stiffness of adding an aldosterone receptor inhibitor to the medication CKD patients are already taking. Besides the primary end point which is Pulse wave velocity (PWV), arterial stiffness is also quantified thorough ambulatory blood pressure measurements.


Options:
A: Arm Label: Spironolactone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Spironolactone, Drug: Standard care | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Standard care | Arm Label: Observational; Type: OTHER; Interventions: Drug: Standard care | Intervention Type: DRUG; Name: Spironolactone; Assigned to Arm(s): Spironolactone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Standard care; Assigned to Arm(s): Observational, Placebo, Spironolactone
B: Arm Label: Spironolactone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Spironolactone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Spironolactone; Assigned to Arm(s): Spironolactone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Eplerenone | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Eplerenone; Assigned to Arm(s): Treatment
D: Arm Label: Finerenone (BAY94-8862) (1.25 mg); Type: EXPERIMENTAL; Interventions: Drug: Finerenone (BAY94-8862) | Arm Label: Finerenone (BAY94-8862)(2.5 mg); Type: EXPERIMENTAL; Interventions: Drug: Finerenone (BAY94-8862) | Arm Label: Finerenone (BAY94-8862)(5 mg); Type: EXPERIMENTAL; Interventions: Drug: Finerenone (BAY94-8862) | Arm Label: Finerenone (BAY94-8862)(7.5 mg); Type: EXPERIMENTAL; Interventions: Drug: Finerenone (BAY94-8862) | Arm Label: Finerenone (BAY94-8862) (10 mg); Type: EXPERIMENTAL; Interventions: Drug: Finerenone (BAY94-8862) | Arm Label: Finerenone (BAY94-8862) (15 mg); Type: EXPERIMENTAL; Interventions: Drug: Finerenone (BAY94-8862) | Arm Label: Finerenone (BAY94-8862)(20 mg); Type: EXPERIMENTAL; Interventions: Drug: Finerenone (BAY94-8862) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Finerenone (BAY94-8862); Assigned to Arm(s): Finerenone (BAY94-8862) (1.25 mg), Finerenone (BAY94-8862) (10 mg), Finerenone (BAY94-8862) (15 mg), Finerenone (BAY94-8862)(2.5 mg), Finerenone (BAY94-8862)(20 mg), Finerenone (BAY94-8862)(5 mg), Finerenone (BAY94-8862)(7.5 mg) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C